CD19 and acute lymphoblastic leukemia: CD19-CAR T cell therapy has been a medical breakthrough in the treatment of pediatric ALL, demonstrated by its outstanding clinical success, which exceeds previous therapies including allo-HSCT and blinatumomab treatment in r/r patients considered to be incurable with a shortened life expectancy [2,17].